Company profile: AC Immune
1.1 - Company Overview
Company description
- Provider of therapeutic and diagnostic products targeting misfolded proteins in neurodegenerative diseases. A Swiss clinical-stage biopharma with three candidates in trials, its pipeline includes ACI-24.060 (anti-Abeta), Semorinemab (anti-Tau), ACI-35.030 (anti-pTau), Morphomer Tau, PI-2620 (Tau-PET tracer), and ACI-7104.056 (anti-alpha-synuclein).
Products and services
- ACI-24.060: A custom-engineered anti‑Abeta active immunotherapy that elicits antibodies against misfolded Abeta to prevent accumulation and enhance clearance of cerebral amyloid plaques
- ACI-35.030: A target-specific anti‑pTau active immunotherapy that induces antibodies against extracellular phosphorylated Tau to prevent and reduce the spread of pathological Tau
- Semorinemab: A precision-engineered anti‑Tau monoclonal antibody that intercepts extracellular Tau to halt cell‑to‑cell propagation of pathological Tau species
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to AC Immune
Jazz Pharmaceuticals
HQ: United States
Website
- Description: Provider of specialty pharmaceuticals for underserved neurology and psychiatry markets. Includes Xyrem and Xywav for cataplexy and excessive daytime sleepiness in narcolepsy; Epidiolex for seizures in Lennox-Gastaut syndrome, Dravet syndrome, or Tuberous Sclerosis Complex; Vyxeos for acute myeloid leukemia; Zepzelca for metastatic small cell lung cancer; Defitelio for hepatic veno-occlusive disease.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Jazz Pharmaceuticals company profile →
Coaxia
HQ: United States
Website
- Description: Provider of medical device research and development focused on therapy and treatment solutions for cerebral ischemia; based in Minneapolis, MN.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Coaxia company profile →
Synchroneuron
HQ: United States
Website
- Description: Provider of biopharmaceutical therapies under development for tardive dyskinesia and other related movement disorders, including lead candidate SNC-102, a sustained-release formulation of acamprosate calcium in phase 2 trials for tardive dyskinesia and Tourette syndrome.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Synchroneuron company profile →
Inbrain Neuroelectronics
HQ: Spain
Website
- Description: Provider of graphene-based brain-computer interface therapeutics and precision neurology solutions that combine high-resolution, skin-like BCI decoding with micrometric modulation in a closed loop to deliver adaptive, personalized treatments for Parkinson’s disease, epilepsy, and stroke. Offerings include implantable neural processors, an AI-powered therapy platform, and Innervia systems for vagus nerve modulation.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Inbrain Neuroelectronics company profile →
Reviva Pharma
HQ: United States
Website
- Description: Provider of clinical-stage pharmaceutical therapies, including Brilaroxazine (RP5063), a serotonin and dopamine receptor modulator in development for neuropsychiatric conditions such as schizophrenia, bipolar disorder, major depressive disorder, Alzheimer's disease, Parkinson's disease psychosis, and ADHD, and RP1208, a triple reuptake inhibitor for depression and obesity.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Reviva Pharma company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for AC Immune
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to AC Immune
2.2 - Growth funds investing in similar companies to AC Immune
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for AC Immune
4.2 - Public trading comparable groups for AC Immune
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →